A comprehensive proteomics study on platelet concentrates: Platelet proteome, storage time and Mirasol pathogen reduction technology

Platelets

Volumn 30, Issue 3, 2019, Pages 368-379

  Salunkhe, Vishal ^a   De Cuyper, Iris M ^a   Papadopoulos, Petros ^b   van der Meer, Pieter F ^c   Daal, Brunette B ^c   Villa Fajardo, María ^b   de Korte, Dirk ^a,c   van den Berg, Timo K ^a   Gutiérrez, Laura ^a,b,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c CENTRAL LABORATORY   (Netherlands)

^d INSTITUTO DE INVESTIGACIÓN SANITARIA DEL PRINCIPADO DE ASTURIAS ISPA   (Spain)

Author keywords

Blood safety; pathogen inactivation technologies; platelet function tests; platelet transfusion; proteomics; storage time

Indexed keywords

2,4 DIENOYL COENZYME A REDUCTASE (NADPH); BETA2 GLYCOPROTEIN 1; C4B BINDING PROTEIN ALPHA CHAIN; COMPLEMENT COMPONENT C4B BINDING PROTEIN; COMPLEMENT FACTOR H; EMILIN 1 PROTEIN; ENDONUCLEASE DOMAIN CONTAINING 1 PROTEIN; ENTACTIN; FUMARATE HYDRATASE; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN 1; MALECTIN PROTEIN; MULTIMERIN 1 PROTEIN; NIDOGEN 1; NIDOGEN 2; PLATELET GLYCOPROTEIN V; PROTEIN ARGININE METHYLTRANSFERASE; PROTEOME; PYRROLINE 5 CARBOXYLATE DEHYDROGENASE; SYNAPTIC VESICLE MEMBRANE PROTEIN VAT 1 HOMOLOG; THROMBOCYTE CONCENTRATE; THROMBOSPONDIN 1; TRANSMEMBRANE EMP24 DOMAIN CONTAINING PROTEIN 10; TRYPSIN; TSC22 DOMAIN FAMILY PROTEIN 3; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

AMINO ACID SEQUENCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERIUM; BLOOD TRANSFUSION; CELL MEMBRANE; CLUSTER ANALYSIS; DEGRANULATION; FLOW CYTOMETRY; IN VITRO STUDY; MASS SPECTROMETRY; METABOLISM; MICROBIOLOGICAL EXAMINATION; MITOCHONDRION; NONHUMAN; PARASITE; PATHOGEN INACTIVATION TECHNOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PLATELET AGGREGATION ASSAY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEOMICS; SAFETY; STORAGE TEMPERATURE; TECHNOLOGY; THROMBOCYTE; THROMBOCYTE PRESERVATION; THROMBOCYTE SHAPE; VIRUS; WESTERN BLOTTING; BLOOD CLOTTING PARAMETERS; HUMAN; PROCEDURES;

BLOOD PLATELETS; HUMANS; PLATELET FUNCTION TESTS; PROTEOME; PROTEOMICS;

EID: 85044219834     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537104.2018.1447658     Document Type: Article

References (61)

1. Allain JP, Bianco C, Blajchman MA, Brecher ME, Busch M, Leiby D, Lin L, Stramer S. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev. 2005;19(2):110–126.
2. Allain JP, Stramer SL, Carneiro-Proietti AB, Martins ML, Lopes da Silva SN, Ribeiro M, Proietti FA, Reesink HW. Transfusion-transmitted infectious diseases. Biologicals. 2009;37(2):71–77.
3. Cable RG, Leiby DA., Risk and prevention of transfusion-transmitted babesiosis and other tick-borne diseases. Curr Opin Hematol. 2003;10(6):405–411.
4. Salunkhe V, van der Meer PF, de Korte D, Seghatchian J, Gutierrez L., Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Apher Sci. 2015;52(1):19–34.
5. Brecher ME, Hay SN., Bacterial contamination of blood components. Clin Microbiol Rev. 2005;18(1):195–204.
6. Kuehnert MJ, Roth VR, Haley NR, Gregory KR, Elder KV, Schreiber GB, Arduino MJ, Holt SC, Carson LA, Banerjee SN, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion. 2001;41(12):1493–1499.
7. Hervig T, Seghatchian J, Apelseth TO., Current debate on pathogen inactivation of platelet concentrates--to use or not to use? Transfus Apher Sci. 2010;43(3):411–414.
8. Seghatchian J, de Sousa G., Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci. 2006;35(3):189–196.
9. Hardwick CC, Herivel TR, Hernandez SC, Ruane PH, Goodrich RP., Separation, identification and quantification of riboflavin and its photoproducts in blood products using high-performance liquid chromatography with fluorescence detection: a method to support pathogen reduction technology. Photochem Photobiol. 2004;80(3):609–615.
10. Kumar V, Lockerbie O, Keil SD, Ruane PH, Platz MS, Martin CB, Ravanat JL, Cadet J, Goodrich RP., Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol. 2004;80:15–21.
11. Li J, Goodrich L, Hansen E, Edrich R, Gampp D, Goodrich RP., Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage. Transfusion. 2005;45(11):1750–1758.
12. Marschner S, Goodrich R., Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light. Transfus Med Hemother. 2011;38(1):8–18.
13. Keil SD, Bengrine A, Bowen R, Marschner S, Hovenga N, Rouse L, Gilmour D, Duverlie G, Goodrich RP., Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment. Transfusion. 2015;55(7):1736–1744.
14. Keil SD, Hovenga N, Gilmour D, Marschner S, Goodrich R., Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination. J Vis Exp. 2015;102:e52820.
15. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP., Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion. 2004;44(6):877–885.
16. Asano H, Lee CY, Fox-Talbot K, Koh CM, Erdinc MM, Marschner S, Keil S, Goodrich RP, Baldwin WM, 3rd. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation. 2007;84(9):1174–1182.
17. Fast LD, DiLeone G, Cardarelli G, Li J, Goodrich R., Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-gamma c-/- double knockout mice. Transfusion. 2006;46(9):1553–1560.
18. Fast LD, Dileone G, Li J, Goodrich R., Functional inactivation of white blood cells by Mirasol treatment. Transfusion. 2006;46(4):642–648.
19. Fast LD, DiLeone G, Marschner S., Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. Transfusion. 2011;51(7):1397–1404.
20. Marschner S, Fast LD, Baldwin WM, 3rd, Slichter SJ, Goodrich RP., White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion. 2010;50(11):2489–2498.
21. Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP., Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev. 2008;22(2):133–153.
22. Mirasol Clinical Evaluation Study G. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion. 2010;50(11):2362–2375.
23. Li J, Lockerbie O, de Korte D, Rice J, McLean R, Goodrich RP., Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion. 2005;45(6):920–926.
24. Marrocco C, D’Alessandro A, Girelli G, Zolla L., Proteomic analysis of platelets treated with gamma irradiation versus a commercial photochemical pathogen reduction technology. Transfusion. 2013;53(8):1808–1820.
25. Perez-Pujol S, Tonda R, Lozano M, Fuste B, Lopez-Vilchez I, Galan AM, Li J, Goodrich R, Escolar G., Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion. 2005;45(6):911–919.
26. Picker SM, Steisel A, Gathof BS., Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion. 2008;48(8):1685–1692.
27. Zeddies S, De Cuyper IM, van der Meer PF, Daal BB, de Korte D, Gutierrez L, Thijssen-Timmer DC., Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. Transfusion. 2014;54(9):2292–2300.
28. Prudent M, D’Alessandro A, Cazenave JP, Devine DV, Gachet C, Greinacher A, Lion N, Schubert P, Steil L, Thiele T, et al. Proteome changes in platelets after pathogen inactivation--an interlaboratory consensus. Transfus Med Rev. 2014;28(2):72–83.
29. Rijkers M, van der Meer PF, Bontekoe IJ, Daal BB, de Korte D, Leebeek FW, Voorberg J, Jansen AJ., Evaluation of the role of the GPIb-IX-V receptor complex in development of the platelet storage lesion. Vox Sang. 2016;111(3):247–256.
30. Van Der Meer, PFY, P.F.,; van Geloven, N.,; van Wordragen-Vlaswinkel, R.,; van der Bom, A.,; Kerkhoffs, J.-L., ASH 2017 Conference Abstracts: Hemostatic Efficacy of Pathogen-Inactivated Buffy Coat-Derived Platelet Concentrates in Hemato-Oncological Patients: Outcomes of the Prepares Trial. Blood. 2017;130(Suppl 1):704.
31. Burkhart JM, Vaudel M, Gambaryan S, Radau S, Walter U, Martens L, Geiger J, Sickmann A, Zahedi RP., The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood. 2012;120(15):e73–82.
32. Yu YS, M.,; Pieper, R. A spinnable and automatable StageTip for high throughput peptide desalting and proteomics. Protocol Exchange. 2014;doi:10.1038/protex.2014.033.
33. Cox J, Mann M., MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008;26(12):1367–1372.
34. Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M., Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res. 2011;10(4):1794–1805.
35. Luber CA, Cox J, Lauterbach H, Fancke B, Selbach M, Tschopp J, Akira S, Wiegand M, Hochrein H, O’Keeffe M, et al. Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. Immunity. 2010;32(2):279–289.
36. Tusher VG, Tibshirani R, Chu G., Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98(9):5116–5121.
37. Deutsch EW, Csordas A, Sun Z, Jarnuczak A, Perez-Riverol Y, Ternent T, Campbell DS, Bernal-Llinares M, Okuda S, Kawano S, et al. The ProteomeXchange consortium in 2017: supporting the cultural change in proteomics public data deposition. Nucleic Acids Res. 2017;45(D1):D1100–D1106.
38. Perez-Riverol Y, Xu QW, Wang R, Uszkoreit J, Griss J, Sanchez A, Reisinger F, Csordas A, Ternent T, Del-Toro N, et al. PRIDE Inspector Toolsuite: Moving Toward a Universal Visualization Tool for Proteomics Data Standard Formats and Quality Assessment of ProteomeXchange Datasets. Mol Cell Proteomics. 2016;15(1):305–317.
39. Vizcaino JA, Csordas A, del-Toro N, Dianes JA, Griss J, Lavidas I, Mayer G, Perez-Riverol Y, Reisinger F, Ternent T, et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 2016;44(D1):D447–456.
40. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013;41(Database issue):D808–815.
41. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, Doerks T, Julien P, Roth A, Simonovic M, et al. STRING 8--a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 2009;37(Database issue):D412–416.
42. De Cuyper IM, Meinders M, van de Vijver E, de Korte D, Porcelijn L, de Haas M, Eble JA, Seeger K, Rutella S, Pagliara D, et al. A novel flow cytometry-based platelet aggregation assay. Blood. 2013;121(10):e70–80.
43. Johnson L, Marks D., Treatment of Platelet Concentrates with the Mirasol Pathogen Inactivation System Modulates Platelet Oxidative Stress and NF-kappaB Activation. Transfus Med Hemother. 2015;42(3):167–173.
44. Leitner GC, List J, Horvath M, Eichelberger B, Panzer S, Jilma-Stohlawetz P., Additive solutions differentially affect metabolic and functional parameters of platelet concentrates. Vox Sang. 2016;110(1):20–26.
45. Ponschab M, Schlimp CJ, Zipperle J, Gabriel C, Sussner S, Cadamuro J, Gratz J, Redl H, Schochl H., Platelet function in reconstituted whole blood variants: An observational study over 5 days of storage time. J Trauma Acute Care Surg. 2015;79(5):797–804.
46. Shams Hakimi C, Hesse C, Wallen H, Boulund F, Grahn A, Jeppsson A., In vitro assessment of platelet concentrates with multiple electrode aggregometry. Platelets. 2015;26(2):132–137.
47. Maynard DM, Heijnen HF, Gahl WA, Gunay-Aygun M., The alpha-granule proteome: novel proteins in normal and ghost granules in gray platelet syndrome. J Thromb Haemost. 2010;8(8):1786–1796.
48. Seghatchian J, Krailadsiri P., The platelet storage lesion. Transfus Med Rev. 1997;11(2):130–144.
49. Winkler AM, Sheppard CA, Culler EE, Myers RL, Duncan A, Castillejo MI, Hillyer CD, Josephson CD., Effects of storage duration and volume on the quality of leukoreduced apheresis-derived platelets: implications for pediatric transfusion medicine. Transfusion. 2010;50(10):2193–2198.
50. Rinalducci S, Zolla L., Biochemistry of storage lesions of red cell and platelet concentrates: A continuous fight implying oxidative/nitrosative/phosphorylative stress and signaling. Transfus Apher Sci. 2015;52(3):262–269.
51. Galan AM, Lozano M, Molina P, Navalon F, Marschner S, Goodrich R, Escolar G., Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function. Transfusion. 2011;51(4):808–815.
52. Ostrowski SR, Bochsen L, Windelov NA, Salado-Jimena JA, Reynaerts I, Goodrich RP, Johansson PI., Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion. 2011;51(2):344–356.
53. Prudent M, Sonego G, Abonnenc M, Tissot JD, Lion N., LC-MS/MS analysis and comparison of oxidative damages on peptides induced by pathogen reduction technologies for platelets. J Am Soc Mass Spectrom. 2014;25(4):651–661.
54. Reikvam H, Marschner S, Apelseth TO, Goodrich R, Hervig T., The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution. Blood Transfus. 2010;8(3):186–192.
55. Schubert P, Culibrk B, Coupland D, Scammell K, Gyongyossy-Issa M, Devine DV., Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage. Transfusion. 2012;52(2):397–408.
56. Chen Z, Schubert P, Culibrk B, Devine DV., p38MAPK is involved in apoptosis development in apheresis platelet concentrates after riboflavin and ultraviolet light treatment. Transfusion. 2015;55(4):848–857.
57. Schubert P, Coupland D, Culibrk B, Goodrich RP, Devine DV., Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment. Transfusion. 2013;53(12):3164–3173.
58. Blair P, Flaumenhaft R., Platelet alpha-granules: basic biology and clinical correlates. Blood Rev. 2009;23(4):177–189.
59. Martino-Echarri E, Fernandez-Rodriguez R, Rodriguez-Baena FJ, Barrientos-Duran A, Torres-Collado AX, Plaza-Calonge Mdel C, Amador-Cubero S, Cortes J, Reynolds LE, Hodivala-Dilke KM, et al. Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2. Int J Cancer. 2013;133(10):2315–2324.
60. Wu C, Chung AE., Potential role of entactin in hemostasis. Specific interaction of entactin with fibrinogen A alpha and B beta chains. J Biol Chem. 1991;266(28):18802–18807.
61. van der Meer PF., PAS or plasma for storage of platelets? A concise review. Transfus Med. 2016;26(5):339–342.